Advertisement

Analyse der Immunantwort nach neoadjuvanter Immuntherapie mit dem humanen monoklonalen Antikörper SC-1 beim Magenkarzinom

  • Udo Lorenz
  • B. Illert
  • K. Ullrichs
  • H. B. Reith
  • W. Timmermann
  • H. P. Vollmers
  • A. Thiede
Conference paper
Part of the Deutsche Gesellschaft für Chirurgie book series (DTGESCHIR, volume 31)

Abstract

Background: Neoadjuvant therapy for gastric cancer patients with the apoptosis inducing human monoclonal antibody SC-1 might be a new therapeutical approach. For further evaluation of antibody SC-1 the perioperative immune function of patients was explored in this prospective study. Methods: Twenty one gastric cancer patients who underwent total gastrectomy divided into 11 patients (mean (SD) age 64.9 (10.3) years) with neoadjuvant SC-1 antibody therapy (study group) and 10 patients (mean (SD) age 63.6 (9.3) years) without antibody therapy (control group) were investigated for immunologic alterations based on the change of cytokine levels such as tumor necrosis factor (TNF)-α, sFas ligand, interleukin-6 (IL-6), interferon (IFN)-γ, interleukin-12 (IL-12), neopterin and rantes. Additionally, blood lymphocyte subsets were characterized according to the following cluster of differentiation (CD) numbers: CD3, CD4, CD8, CD14, CD19, CD16/56 and quantified as a percentage of total lymphocytes. Results: The level of TNF-α was significantly increased after SC-1 antibody therapy. The perioperative course of other cytokine concentrations were not significantly changed after delivery of SC-1 antibody. There was no significant relationship between change of lymphocyte subsets and antibody therapy. Conclusions: Regarding the data, the delivery of antibody SC-1 leads not to a profound alteration neither in circulating cytokines nor lymphocytes. Especially perioperative immune function in gastric cancer patients with SC-1 antibody therapy seems to be not impaired.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Vollmers HP, Dämmrich J, Ribbert H, Wozniak E und Müller-Hermelink HK (1995) Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 76: 550 - 558PubMedCrossRefGoogle Scholar
  2. 2.
    Vollmers HP, Zimmermann U, Krenn V, Timmermann W, Illert B, Hensel F, Hermann R, Thiede A, Wilhelm M, Rückle-Lanz H, Reindl L und Müller-Hermelink HK (1998) Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol. Rep. 5: 549 - 552PubMedGoogle Scholar
  3. 3.
    Hensel F, Hermann R, Schubert C, Abé N, Schmidt K, Franke A, Shevchenko A, Mann M, MüllerHermelink HK und Vollmers HP (1999) Characterization of Glycosylphosphatidylinositol-linked Molecule CD55/Decay-accelerating Factor as the Receptor for Antibody SC-1-induced Apoptosis. Cancer Research 59: 5299 - 5306PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • Udo Lorenz
    • 1
    • 3
  • B. Illert
    • 1
  • K. Ullrichs
    • 1
  • H. B. Reith
    • 1
  • W. Timmermann
    • 1
  • H. P. Vollmers
    • 2
  • A. Thiede
    • 1
  1. 1.Chirurgische Klinik und PoliklinikGermany
  2. 2.Pathologisches InstitutUniversität WürzburgGermany
  3. 3.Chirurgische Klinik und PoliklinikUniversität WürzburgWürzburgGermany

Personalised recommendations